Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytesPARKER, Janice C; MCPHERSON, R. Kirk; DEKKER, Koen A et al.Diabetes (New York, NY). 2000, Vol 49, Num 12, pp 2079-2086, issn 0012-1797Article

Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitorsERCAN-FANG, Nacide; TAYLOR, Miriam R; TREADWAY, Judith L et al.American journal of physiology. Endocrinology and metabolism. 2005, Vol 52, Num 3, pp E366-E372, issn 0193-1849Article

The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbitsFLYNN, David M; SMITH, Andrew H; KNIGHT, Delvin R et al.Cardiovascular drugs and therapy. 2005, Vol 19, Num 5, pp 337-346, issn 0920-3206, 10 p.Article

Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitorTRACEY, W. Ross; TREADWAY, Judith L; MUTCHLER, Alison K et al.American journal of physiology. Heart and circulatory physiology. 2004, Vol 55, Num 3, pp H1177-H1184, issn 0363-6135Article

Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: Synthesis, in vitro characterization, and X-ray crystallographyWRIGHT, Stephen W; CARLO, Anthony A; NESTOR, Nestor B et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 18, pp 3865-3877, issn 0022-2623Article